Resmed Governance
Board of Directors

Carol Burt has served as a Resmed director since November 2013 and is chair of the nominating & governance committee. She is also a member of the audit and compliance, privacy and quality committees. Effective November 15, 2026, Ms. Burt will serve as Resmed’s Lead Director.

Ms. Burt is a private investor with more than 35 years of experience in corporate governance, operations, strategy, finance, mergers and acquisitions, and investment banking. Since 2013, Ms. Burt has served as a senior advisor and a member of the operating council of Consonance Capital Partners, a New York-based private equity firm focused on investments in the healthcare industry. Ms. Burt serves on the board of IQVIA Holdings Inc. (NYSE: IQV), where she chairs the leadership development and compensation committee and is a member of the audit committee, and also serves on the board of WellDyne.

Prior to their sale, Ms. Burt served on the public boards of four NYSE companies: Envision Healthcare, Transitional Hospitals, Vanguard Health Systems, and WellCare Health Plans. She also previously served on the boards of Global Medical Response and KEPRO. Through her public board service, Ms. Burt has served, or currently serves, as chair of audit, compensation and leadership development, compliance, and nominating and governance committees.

Ms. Burt was formerly senior vice president of corporate finance and development of WellPoint, Inc. (now Elevance Health, Inc.), where she was part of the executive team that built WellPoint from a single-state health plan into one of the leading U.S. health benefits companies. Before WellPoint, Ms. Burt was senior vice president and treasurer of American Medical Response. Previously, she spent 16 years at Chase Securities, Inc. (now JPMorgan Chase & Co.), most recently as founder, managing director, and head of the Health Care Banking Group.

Ms. Burt is a member of Women Corporate Directors and the International Women’s Forum. She graduated magna cum laude from the University of Houston with a Bachelor of Business Administration.

Jan De Witte has served as a Resmed director since May 2019 and is a member of its audit, compensation and leadership development, and nominating and governance committees.

Mr. De Witte is an accomplished public company chief executive officer and board director with extensive experience leading international growth and transformation for global technology and medtech companies. He currently serves as an Operating Partner at GHO Capital Partners, a leading European healthcare specialist private equity investor.

His board and governance experience includes a current directorship at Elekta AB, where he is a member of the Strategy and Innovation Committee, and chairmanship of FotoFinder Group GmbH. His previous public-company directorships include Integra LifeSciences and Barco N.V. He has also served as a director of the Advanced Medical Technology Association (AdvaMed).

Mr. De Witte most recently served as president, chief executive officer and a director of Integra LifeSciences. Before joining Integra in 2021, he served as chief executive officer and a director of Barco N.V. Before joining Barco in 2016, Mr. De Witte spent 17 years with General Electric Company in progressive leadership roles, including president and CEO of GE Global Healthcare IT, with responsibilities spanning Europe, the Middle East, China, Asia-Pacific and the Americas.

Mr. De Witte began his career in operations roles at Procter & Gamble in Europe and as a senior consultant at McKinsey & Co. He holds bachelor’s and Master of Science degrees in electromechanical engineering from KU Leuven in Belgium, with Greatest Distinction for his master’s degree, and an M.B.A. from Harvard Business School.

Christopher DelOrefice has served as a Resmed director since August 2024 and is chair of the audit committee.

Mr. DelOrefice is a proven financial executive and currently serves as Chief Financial Officer of Ulta Beauty (NASDAQ: ULTA), a leading global beauty retail company. He joined Ulta Beauty as Chief Financial Officer in December 2025.

From September 2021 to December 2025, Mr. DelOrefice served as Executive Vice President and Chief Financial Officer of Becton, Dickinson and Company (BD), a leading global medical technology company. Prior to BD, he spent more than 20 years at Johnson & Johnson in a variety of senior finance leadership roles. From August 2018 to September 2021, he served as Vice President, Investor Relations. Earlier roles included serving as chief financial officer of both the Consumer and Medical Devices segments for North America.

Mr. DelOrefice holds a Bachelor of Science in Accounting and an M.B.A. from Villanova University. He is a Certified Public Accountant (inactive).

Karen Drexler has served as a Resmed director since November 2017. She is chair of the compensation and leadership development committee and a member of the compliance, privacy and quality and nominating and governance committees.

Ms. Drexler is a serial entrepreneur with expertise in digital health, medical devices and diagnostics. She currently serves on the boards of Outset Medical (NASDAQ: OM), where she chairs the nominating and corporate governance committee and is a member of the compensation committee, and EBR Systems, Inc. (ASX: EBR), where she chairs the nomination and remuneration committee and is a member of the audit and risk committee. She previously served on the board of Tivic Health (NASDAQ: TIVC) from 2019 to 2024.

Ms. Drexler also serves on private-company boards and acts as a senior strategic advisor for early-stage companies. From 2016 to 2020, she was CEO and a board member of Sandstone Diagnostics, Inc. She was founder, president and CEO of Amira Medical Inc., a company focused on minimally invasive glucose monitoring technology, until its sale to Roche Holding AG.

Ms. Drexler is an active mentor and advisor with Astia and serves on the Women’s Health Council for Springboard. She has been elected to the American Institute for Medical and Biological Engineering (AIMBE) College of Fellows.

Ms. Drexler graduated magna cum laude with a B.S.E. in chemical engineering from Princeton University and earned an M.B.A. with honors from the Stanford University Graduate School of Business.

Michael “Mick” Farrell was appointed Resmed’s Chief Executive Officer and has served as a director since March 2013. In January 2023, he was appointed Chairman of the Board. Mick joined Resmed in 2000 and previously served as president of the Americas region, senior vice president of the global sleep apnea diagnostic and therapeutic business, and in senior marketing and business development roles. Before joining Resmed, he worked in management consulting for biotechnology, chemicals and metals manufacturing companies, including Arthur D. Little, Sanofi Genzyme, Dow and BHP

Mick serves as Chair of the Board of Directors of the Advanced Medical Technology Association (AdvaMed). He has served as a director of Zimmer Biomet (NYSE: ZBH) since 2014 and became its Lead Independent Director in 2025. He is also a member of Zimmer Biomet’s Compensation and Management Development Committee and Quality, Regulatory and Technology Committee.

Mick volunteers as a trustee for nonprofit organizations including the University of California, San Diego Foundation, Rady Children’s Hospital and Father Joe’s Villages’ project for the homeless in San Diego. He also chairs the University of California San Diego Rady School of Management Dean’s Advisory Council. He was an honoree of the American Australian Association in 2025 and received the Public Service Star Award as part of the Singapore National Day Awards in 2026.

Mick holds a Bachelor of Engineering with first-class honors from the University of New South Wales, a Master of Science in chemical engineering from the Massachusetts Institute of Technology, and a Master of Business Administration from the MIT Sloan School of Management.

Peter Farrell is Resmed’s founder and Chairman Emeritus. He has been a director since Resmed’s inception in May 1989 and served as Chairman of the Board until January 2023, when he became Chairman Emeritus. Dr. Farrell served as Chief Executive Officer from July 1990 to December 2007 and again from February 2011 to March 2013. Since January 2014, he has served as a non-officer employee of Resmed.

Before founding Resmed, Dr. Farrell served as Managing Director of the Baxter Center for Medical Research Pty Ltd. From 1978 to 1989, he was Foundation Director of the Graduate School for Biomedical Engineering at the University of New South Wales, where he currently serves as a visiting professor and was formerly chair of the UNSW Centre for Innovation and Entrepreneurship.

Dr. Farrell serves on the board of Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT), where he is a director, former Board Chair, and a member of the compensation and nominating and corporate governance committees. He previously served on the public-company boards of NuVasive, Inc. and Evolus, Inc.

Dr. Farrell is a member of the MIT Dean of Engineering’s Advisory Council and previously served on the Visiting Committee of the Harvard-MIT Health Sciences & Technology Program. He also serves on the faculty advisory board of the Jacobs School of Engineering at the University of California, San Diego, the Board of Trustees of Scripps Research Institute, and the Executive Council of the Division of Sleep Medicine at Harvard Medical School.

Dr. Farrell holds a B.E. in chemical engineering with honors from the University of Sydney, an S.M. in chemical engineering from MIT, a Ph.D. in chemical engineering and bioengineering from the University of Washington, Seattle, and a D.Sc. from the University of New South Wales.

Harjit Gill has served as a Resmed director since 2018. She is chair of the compliance, privacy and quality committee and a member of the audit and compensation and leadership development committees.

Ms. Gill is the former Chief Executive Officer of the Asia Pacific Medical Technology Association (APACMed), the regional association representing the medical device, equipment and in-vitro diagnostics industry in Asia Pacific. She served as APACMed’s Chief Executive Officer from February 2019 to December 2025.

Ms. Gill currently serves as a director of Alticor, Inc., a private holding company for Amway, where she is a member of the audit and cybersecurity committees. From 2019 to December 2025, she served as a director and member of the Innovation Board of MAS Holdings, one of the largest apparel technology companies in Southeast Asia.

Earlier in her career, Ms. Gill spent 25 years with Royal Philips in progressive leadership roles, including Executive Vice President and Chief Executive Officer for Philips ASEAN & Pacific. She has extensive experience in consumer healthcare and international sales and marketing, including across Europe, Asia and the Middle East.

Ms. Gill serves as a member of the academic committee of the China-ASEAN science and technology cooperation center for public health at Peking University. She holds a Bachelor of Arts with honors in combined studies from the University of Manchester.

John Hernandez has served as a Resmed director since November 2021 and is a member of its audit and compliance, privacy and quality committees.

Dr. Hernandez is Head of Clinical Research, Health Economics and Outcomes Research at Google, a subsidiary of Alphabet Inc. He joined Alphabet in 2016 and has built and led teams at Verily and Google leveraging artificial intelligence to promote healthy lifestyles, diagnose cancer and prevent blindness, among other applications.

Dr. Hernandez has more than 30 years of experience as a health technology industry executive, researcher and consultant, with expertise in clinical research, health economics, market access, real-world evidence, artificial intelligence and global commercial strategy. Prior to joining Alphabet, he was Vice President of Global Health Economics and Outcomes Research at Abbott Laboratories and Vice President of Clinical Research and Health Economics at Boston Scientific Corporation.

Dr. Hernandez is widely published in scientific journals and lectures on digital health strategy, health policy, health economics, healthcare technology assessment, value-based payments and real-world evidence strategies.

Dr. Hernandez holds a Bachelor of Arts from the University of North Carolina at Chapel Hill, a master’s degree in health policy analysis from the RAND School of Public Policy, and a Ph.D. in health policy from the RAND School of Public Policy.

Nicole Mowad-Nassar has served as a Resmed director since August 2025 and is a member of the compliance, privacy and quality committee.

Ms. Mowad-Nassar is Senior Vice President, AbbVie, and President, Global Allergan Aesthetics. She has extensive experience in the pharmaceutical industry as a P&L leader, with expertise spanning commercial strategy, marketing, digital health innovation, patient services, market access and enterprise integration.

From July 2023 to August 2025, Ms. Mowad-Nassar served as Senior Vice President, AbbVie and President, Specialty & U.S. Therapeutics Operations. From January 2020 to July 2023, she served as Vice President, Commercial Analytics & Operations, AbbVie Patient Services. From January 2018 to January 2020, she served as Vice President, Commercial Analytics and Operations and Global Commercial Integration Lead for the Allergan acquisition.

Before joining AbbVie, Ms. Mowad-Nassar spent 2009 to 2017 at Takeda Pharmaceuticals USA in progressive leadership roles, including Vice President and Head of U.S. Business Operations and External Partnerships and Vice President, U.S. Marketing. From 2000 to 2009, she held progressive leadership roles at Abbott Laboratories in the Hospital Products Division and Pharmaceutical Products Division.

Ms. Mowad-Nassar serves on AbbVie’s Environmental, Social & Governance Steering Council and Executive Crisis Management Team. She previously served on the boards of Cristo Rey St. Martin College Prep and Lake Forest High School.

Ms. Mowad-Nassar holds a Bachelor of Arts in Economics from Bucknell University and a Master of Business Administration from the Kellogg School of Management at Northwestern University.

Desney Tan has served as a Resmed director since November 2021 and is a member of the compensation and leadership development and nominating and governance committees.

Dr. Tan is a Venture Partner at SeaX Ventures, a global early-stage venture-capital fund focused on deep technology companies, a role he has held since August 2026. He previously served at Microsoft in a series of senior innovation and research leadership roles, including Corporate Vice President and Managing Director of Microsoft Research from 2023 to January 2026, Vice President and Managing Director of Microsoft Health Futures from 2021 to 2023, and Managing Director of Microsoft Healthcare from 2015 to 2021. He joined Microsoft in 2004.

Dr. Tan is a technology executive who has built and led multidisciplinary global innovation teams. He is the named inventor on more than 100 granted patents and author of numerous academic publications on topics relevant to Resmed’s long-term strategy, including artificial intelligence, real-world evidence, machine learning and human-computer interaction.

Since 2007, Dr. Tan has served as an affiliate professor of computer science and engineering at the University of Washington Seattle. He serves on the Washington Research Foundation’s board of directors, is a senior advisor and chief technologist to IntuitiveX, and serves as an advisor to Proprio and NewDays.

Dr. Tan holds a Bachelor of Science, summa cum laude, in computer engineering from the University of Notre Dame and a Ph.D. in computer science from Carnegie Mellon University.

Ron Taylor has served as a Resmed Independent director since January 2005 and its independent lead director since July 1, 2013. He is a member of the audit, compliance, privacy and quality, and nominating and governance committees.

In 1987, Mr. Taylor founded Pyxis Corporation, a manufacturer of automated drug dispensers for hospitals, where he served as chairman, president, and CEO until its purchase by Cardinal Health, Inc., in 1996. For six years before founding Pyxis, Mr. Taylor was responsible for operations and international sales at Hybritech, Inc., a biotechnology company. Before joining Hybritech, he served for 10 years in management roles at Allergan plc (NYSE: AGN), a pharmaceutical company. From 1998-2001, he was a general partner at Enterprise Partners Venture Capital.

Mr. Taylor has served on the board of seven public companies, including Allergan and its predecessor companies from 1994 to 2018, and Red Lion Hotels from 1998 until 2014. He served as Chair of the compensation committee at both companies, as well as a member of the nominating and governance and audit committees. In addition, he has been a director of 14 privately held companies. From 2002 until his appointment to the ResMed board in 2005, he served as chairman of the ResMed Foundation.

Mr. Taylor has a Bachelor of Arts from the University of Saskatchewan and a Master of Arts from the University of California, Irvine.